• Methods A total of 657 consecutive patients (age 63 ± 12 years, 79% men, 21% diabetics, 67% acute coronary syndrome) who received a total of 883 BRS for the treatment of coronary artery stenoses between May 2012 and January 2015 were enrolled in a retrospective registry. (onlinejacc.org)
  • Methods: As a substudy of the optimization with intracoronary, ultrasound (ICUS) to reduce stent restenosis (OPTICUS) study, we analyzed ACE serum levels and the ACE gene polymorphism in 154 patients at 9 different centers. (uni-muenchen.de)
  • Despite the use of Drug eluting stent (DES), the rate of restenosis remains 7% to 16% in diabetic patients, making it a challenging problem in interventional cardiology. (centerwatch.com)
  • We designed a prospective, randomized, controlled study to verify the hypothesis that rosiglitazone, another member of the TZD class, reduces the rate of restenosis in type 2 diabetic patients who have undergone coronary stenting. (diabetesjournals.org)
  • Many studies have shown that hyperinsulinemia and insulin resistance increase neointimal index measured six months after coronary stenting, and that insulin- sensitizers have beneficial effects by decreasing the rate of restenosis. (elsevier.com)
  • Use of first generation DES versus BMS (OR 0.35, 95% CI 0.31 to 0.39) and second generation DES versus first generation DES (OR 0.67, 95% CI 0.58 to 0.77) were independent predictors of lower rates of restenosis. (bmj.com)
  • To evaluate the effect of adding cilostazol to dual antiplatelet therapy (aspirin and thienopyridine) on rates of restenosis after coronary artery stenting. (york.ac.uk)
  • OPN may play a role in the development of restenosis associated with neointimal proliferation. (ahajournals.org)
  • Impaired insulin sensitivity and endothelial dysfunction are important markers in the development of restenosis after coronary stenting. (elsevier.com)
  • Coronary artery minimal luminal diameter favoured triple over dual therapy (mean difference 0.18mm, 95% CI 0.1 to 0.27). (york.ac.uk)
  • This study was a prospective, randomized trial comparing the effect of cilostazol on restenosis with conventional antiplatelet therapy of aspirin. (ahajournals.org)